Pharma industry tariff strategy in 2026: Section 232 effective July 31 covers branded patented drugs; generics and biosimilars excluded. USMCA-qualifying Mexican and Canadian pharma exempt from Section 122 plus Section 232. Supply chain shifts to USMCA partners can be material.
This guide covers Pharma Industry Tariff Strategy. Sector-specific tariff strategy considers HS classification patterns, applicable special tariff regimes (Section 232/301/122), and FTA opportunities.
Practical implementation depends on company size, sector, and operational structure.
Section 232 pharma scope
Branded patented drugs covered. Tiered rates. Generics and biosimilars excluded under current proclamation.
USMCA pharma qualification
Mexican generic manufacturers and Canadian pharma can qualify under USMCA tariff-shift rules.
Supply chain shift options
Ireland and Switzerland sourcing have different Section 232 implications than non-FTA partners. India generics exempt from Section 232.
IEEPA refund recovery
Pharma imports paid IEEPA throughout 2025. Recoverable through CAPE.
Frequently asked questions
When does this apply?
Most relevant for SMB importers in the named sector or facing the named situation.
What documentation matters?
Standard CBP forms, supplier certificates, BOM analysis, and topic-specific records.
What is the timeline?
Initial assessment 2-4 weeks; full implementation 8-16 weeks depending on scope.
What does this cost?
Project work $5,000-$25,000 depending on complexity. Ongoing retainer for active operations.
How do I begin?
Book a 15-minute scoping call. We confirm fit before any engagement.
Get started
Run a sector-specific tariff exposure assessment for your business.